A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01181700 |
Recruitment Status :
Completed
First Posted : August 13, 2010
Last Update Posted : January 24, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pharmacokinetics | Drug: Treatment A Drug: Treatment B Drug: Treatment C Drug: Treatment D Drug: Treatment E Drug: Treatment F Drug: Treatment G | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 42 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers |
Study Start Date : | October 2010 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | January 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment A |
Drug: Treatment A
PF-00241939 300 ug using inhaler A |
Experimental: Treatment B |
Drug: Treatment B
PF-00241939 300 ug using inhaler A |
Experimental: Treatment C |
Drug: Treatment C
PF-00241939 300 ug using inhaler A |
Active Comparator: Treatment D |
Drug: Treatment D
PF-00241939 300 ug using inhaler B |
Active Comparator: Treatment E |
Drug: Treatment E
PF-00241939 300 ug using inhaler B |
Active Comparator: Treatment F |
Drug: Treatment F
PF-00241939 300 ug using inhaler B |
Active Comparator: Treatment G |
Drug: Treatment G
PF-00241939 300 ug using inhaler B |
- Plasma pharmacokinetic parameters: AUClast and Cmax. [ Time Frame: 36 hours ]
- Plasma pharmacokinetic parameters: AUC24, AUCinf, Tmax and half-life. [ Time Frame: 36 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy male and/or female subjects between the ages of 21 and 55 years.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Pregnant or nursing females.
- A positive urine drug screen.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181700
Singapore | |
Pfizer Investigational Site | |
Singapore, Singapore, 188770 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
ClinicalTrials.gov Identifier: | NCT01181700 |
Other Study ID Numbers: |
B0871015 |
First Posted: | August 13, 2010 Key Record Dates |
Last Update Posted: | January 24, 2011 |
Last Verified: | January 2011 |
Respiratory Aspiration Respiration Disorders Respiratory Tract Diseases Pathologic Processes |